The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis

Cancer Biology and Therapy

Volumn 14, Issue 12, 2013, Pages 1158-1166

  Manini, Ivana ^a   Sgorbissa, Andrea ^a   Potu, Harish ^a   Tomasella, Andrea ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Autocrine loop; IFN ; IFNAR; TRAIL; TRAIL R2; USP18

Indexed keywords

ALPHA INTERFERON; CASPASE 3; CASPASE 7; DEISGYLASE UBIQUITIN SPECIFIC PEPTIDASE 18; DEUBIQUITINASE; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; INTERFERON; PROTEINASE; RECOMBINANT PROTEIN; USP18 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; DNA DAMAGE; DOWN REGULATION; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; GENE EXPRESSION; GLIOBLASTOMA; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRYPAN BLUE ASSAY; UPREGULATION; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOPEPTIDASES; HUMANS; INTERFERONS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84891761021     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26525     Document Type: Article

References (39)

1. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32:1341-50; PMID:22580613; http://dx.doi.org/10.1038/onc.2012.164
2. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosisinducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-60; PMID:10224285; http://dx.doi.org/10.1084/jem.189.9.1451 (Pubitemid 29227531)
3. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther 2012; 13:1143-51; PMID:22892844; http://dx.doi.org/10.4161/cbt.21354
4. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3; PMID:9082980; http://dx.doi.org/10.1126/science.276.5309.111 (Pubitemid 27161256)
5. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20; PMID:9325248; http://dx.doi.org/10.1074/jbc.272.41.25417 (Pubitemid 27438841)
6. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97; PMID:9311998; http://dx.doi.org/10.1093/emboj/16.17.5386 (Pubitemid 27380146)
7. Pintzas A, Zhivotovsky B, Workman P, Clarke PA, Linardopoulos S, Martinou JC, Lacal JC, Robine S, Nasioulas G, Andera L. Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. Cancer Biol Ther 2012; 13:458-66; PMID:22406997; http://dx.doi.org/10.4161/cbt.19600
8. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-8; PMID:9242610; http://dx.doi.org/10.1126/science.277.5327.815 (Pubitemid 27366732)
9. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-5; PMID:9217161; http://dx.doi.org/10.1038/40657 (Pubitemid 27297457)
10. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64:3006-8; PMID:15126334; http://dx.doi.org/10.1158/0008-5472.CAN-04-0046 (Pubitemid 38581397)
11. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21:2283-94; PMID:11948412; http://dx.doi.org/10.1038/sj.onc.1205258 (Pubitemid 34407288)
12. Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001; 280:788-97; PMID:11162590; http://dx.doi.org/10.1006/bbrc.2000.4218 (Pubitemid 32924499)
13. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22:3842-52; PMID:12813457; http://dx.doi.org/10.1038/sj.onc.1206520 (Pubitemid 36819657)
14. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010; 5:e10226; PMID:20419107; http://dx.doi.org/10.1371/journal. pone.0010226
15. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res 2007; 67:5880-8; PMID:17575157; http://dx.doi.org/10.1158/0008-5472.CAN-07-0213 (Pubitemid 46985023)
16. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22:4953-63; PMID:12902978; http://dx.doi.org/10.1038/sj.onc.1206656 (Pubitemid 37026394)
17. Inoue H, Shiraki K, Ohmori S, Sakai T, Deguchi M, Yamanaka T, Okano H, Nakano T. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med 2002; 9:521-5; PMID:11956660
18. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res 2006; 66:9235-44; PMID:16982768; http://dx.doi.org/10.1158/0008-5472.CAN-06-0702 (Pubitemid 44521145)
19. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67:4981-8; PMID:17510429; http://dx.doi.org/10.1158/0008-5472.CAN-06-4274
20. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011; 17:4019-30; PMID:21525171; http://dx.doi.org/10.1158/1078-0432.CCR-11-0075
21. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kappaB signaling pathway. Mol Cancer Ther 2011; 10:198-208; PMID:21220502; http://dx.doi.org/10. 1158/1535-7163.MCT-10-0725
22. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, Jia L. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008; 111:2797-805; PMID:18160669; http://dx.doi.org/10.1182/blood- 2007-08-110445
23. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligandinduced apoptosis. J Immunol 2002; 169:847-55; PMID:12097388 (Pubitemid 34753441)
24. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6:975-90; PMID:18049472; http://dx.doi.org/10.1038/nrd2422 (Pubitemid 350201788)
25. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; http://dx.doi.org/10.1023/A:1023668705040 (Pubitemid 36749609)
26. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277:9976-81; PMID:11788588; http://dx.doi.org/10.1074/jbc.M109078200 (Pubitemid 34968105)
27. Sgorbissa A, Brancolini C. IFNs, ISGylation and cancer: Cui prodest? Cytokine Growth Factor Rev 2012; 23:307-14; PMID:22906767; http://dx.doi.org/10. 1016/j.cytogfr.2012.07.003
28. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, Fuchs SY, Shuai K, Zhang DE. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006; 25:2358-67; PMID:16710296; http://dx.doi.org/10.1038/sj.emboj.7601149 (Pubitemid 44012219)
29. Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res 2010; 70:655-65; PMID:20068173; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-1942
30. Foti C, Florean C, Pezzutto A, Roncaglia P, Tomasella A, Gustincich S, Brancolini C. Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Mol Cancer Ther 2009; 8:3140-50; PMID:19887551; http://dx.doi.org/10. 1158/1535-7163.MCT-09-0431
31. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13:1070-7; PMID:17767167; http://dx.doi.org/10.1038/nm1627 (Pubitemid 47517508)
32. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2010; 1805:123-40; PMID:19961901
33. Oh Y, Jeon YJ, Hong GS, Kim I, Woo HN, Jung YK. Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells. Cell Death Differ 2012; 19:1196-207; PMID:22240897; http://dx.doi.org/10.1038/cdd.2011.209
34. Xiao W, Ishdorj G, Sun J, Johnston JB, Gibson SB. Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses. Leuk Lymphoma 2011; 52:1290-301; PMID:21699383; http://dx.doi.org/10.3109/104281 94.2011.567317
35. Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006; 5:1844-53; PMID:16891471; http://dx.doi.org/10.1158/1535-7163.MCT-06-0050 (Pubitemid 44323253)
36. Chen JJ, Shen HC, Rivera Rosado LA, Zhang Y, Di X, Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget 2012; 3:833-42; PMID:22909995
37. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, Kneteman NM, Hao C. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosisinducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res 2007; 67:6946-55; PMID:17638906; http://dx.doi.org/10.1158/0008-5472.CAN-06-3896 (Pubitemid 47105542)
38. Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C. Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 2011; 16:1229-44; PMID:21858676; http://dx.doi.org/10.1007/s10495-011-0639-4
39. Nurtdinov RN, Vasiliev MO, Ershova AS, Lossev IS, Karyagina AS. PLANdbAffy: probe-level annotation database for Affymetrix expression microarrays. Nucleic Acids Res 2010; 38(Database issue):D726-30; PMID:19906711; http://dx.doi.org/10.1093/nar/gkp969